Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Adizutecan + Osimertinib vs Standard Therapy in First-Line EGFR-Mutated Non-Squamous NSCLC (Phase II/III)
ChiCTR2600116886Phase 3Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jan 2026
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of telisotuzumab adizutecan and osimertinib in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Shanghai Chest Hospital. Primary endpoints: Objective response rate (ORR) (Phase II) and Progression-free survival (PFS) (Phase III). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
telisotuzumab adizutecanosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600116886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116886.